5.17
-0.03 (-0.58%)
| Penutupan Terdahulu | 5.20 |
| Buka | 5.20 |
| Jumlah Dagangan | 1,650,364 |
| Purata Dagangan (3B) | 1,824,373 |
| Modal Pasaran | 496,408,096 |
| Harga / Buku (P/B) | 12.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| EPS Cair (TTM) | -1.99 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.39% |
| Nisbah Semasa (MRQ) | 10.18 |
| Aliran Tunai Operasi (OCF TTM) | -144.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.01 M |
| Pulangan Atas Aset (ROA TTM) | -32.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Care Facilities (US) | Bercampur | Bercampur |
| Medical Care Facilities (Global) | Bercampur | Bercampur | |
| Stok | COMPASS Pathways Plc - American | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.75 |
|
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
|
| Sektor | Healthcare |
| Industri | Medical Care Facilities |
| % Dimiliki oleh Orang Dalam | 13.64% |
| % Dimiliki oleh Institusi | 55.92% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (BTIG, 170.79%) | Beli |
| Median | 12.50 (141.78%) | |
| Rendah | 11.00 (Morgan Stanley, 112.77%) | Beli |
| Purata | 12.50 (141.78%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.89 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 05 Nov 2025 | 11.00 (112.77%) | Beli | 5.49 |
| BTIG | 13 Oct 2025 | 14.00 (170.79%) | Beli | 6.29 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Nov 2025 | Pengumuman | Compass Pathways to Participate in Stifel 2025 Healthcare Conference |
| 04 Nov 2025 | Pengumuman | Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months |
| 30 Oct 2025 | Pengumuman | NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression |
| 29 Oct 2025 | Pengumuman | Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors |
| 28 Oct 2025 | Pengumuman | Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |